Cargando…

Transcription Factors in Cancer Development and Therapy

Cancer is a multi-step process and requires constitutive expression/activation of transcription factors (TFs) for growth and survival. Many of the TFs reported so far are critical for carcinogenesis. These include pro-inflammatory TFs, hypoxia-inducible factors (HIFs), cell proliferation and epithel...

Descripción completa

Detalles Bibliográficos
Autores principales: Vishnoi, Kanchan, Viswakarma, Navin, Rana, Ajay, Rana, Basabi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464564/
https://www.ncbi.nlm.nih.gov/pubmed/32824207
http://dx.doi.org/10.3390/cancers12082296
_version_ 1783577394610700288
author Vishnoi, Kanchan
Viswakarma, Navin
Rana, Ajay
Rana, Basabi
author_facet Vishnoi, Kanchan
Viswakarma, Navin
Rana, Ajay
Rana, Basabi
author_sort Vishnoi, Kanchan
collection PubMed
description Cancer is a multi-step process and requires constitutive expression/activation of transcription factors (TFs) for growth and survival. Many of the TFs reported so far are critical for carcinogenesis. These include pro-inflammatory TFs, hypoxia-inducible factors (HIFs), cell proliferation and epithelial–mesenchymal transition (EMT)-controlling TFs, pluripotency TFs upregulated in cancer stem-like cells, and the nuclear receptors (NRs). Some of those, including HIFs, Myc, ETS-1, and β-catenin, are multifunctional and may regulate multiple other TFs involved in various pro-oncogenic events, including proliferation, survival, metabolism, invasion, and metastasis. High expression of some TFs is also correlated with poor prognosis and chemoresistance, constituting a significant challenge in cancer treatment. Considering the pivotal role of TFs in cancer, there is an urgent need to develop strategies targeting them. Targeting TFs, in combination with other chemotherapeutics, could emerge as a better strategy to target cancer. So far, targeting NRs have shown promising results in improving survival. In this review, we provide a comprehensive overview of the TFs that play a central role in cancer progression, which could be potential therapeutic candidates for developing specific inhibitors. Here, we also discuss the efforts made to target some of those TFs, including NRs.
format Online
Article
Text
id pubmed-7464564
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74645642020-09-04 Transcription Factors in Cancer Development and Therapy Vishnoi, Kanchan Viswakarma, Navin Rana, Ajay Rana, Basabi Cancers (Basel) Review Cancer is a multi-step process and requires constitutive expression/activation of transcription factors (TFs) for growth and survival. Many of the TFs reported so far are critical for carcinogenesis. These include pro-inflammatory TFs, hypoxia-inducible factors (HIFs), cell proliferation and epithelial–mesenchymal transition (EMT)-controlling TFs, pluripotency TFs upregulated in cancer stem-like cells, and the nuclear receptors (NRs). Some of those, including HIFs, Myc, ETS-1, and β-catenin, are multifunctional and may regulate multiple other TFs involved in various pro-oncogenic events, including proliferation, survival, metabolism, invasion, and metastasis. High expression of some TFs is also correlated with poor prognosis and chemoresistance, constituting a significant challenge in cancer treatment. Considering the pivotal role of TFs in cancer, there is an urgent need to develop strategies targeting them. Targeting TFs, in combination with other chemotherapeutics, could emerge as a better strategy to target cancer. So far, targeting NRs have shown promising results in improving survival. In this review, we provide a comprehensive overview of the TFs that play a central role in cancer progression, which could be potential therapeutic candidates for developing specific inhibitors. Here, we also discuss the efforts made to target some of those TFs, including NRs. MDPI 2020-08-15 /pmc/articles/PMC7464564/ /pubmed/32824207 http://dx.doi.org/10.3390/cancers12082296 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Vishnoi, Kanchan
Viswakarma, Navin
Rana, Ajay
Rana, Basabi
Transcription Factors in Cancer Development and Therapy
title Transcription Factors in Cancer Development and Therapy
title_full Transcription Factors in Cancer Development and Therapy
title_fullStr Transcription Factors in Cancer Development and Therapy
title_full_unstemmed Transcription Factors in Cancer Development and Therapy
title_short Transcription Factors in Cancer Development and Therapy
title_sort transcription factors in cancer development and therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464564/
https://www.ncbi.nlm.nih.gov/pubmed/32824207
http://dx.doi.org/10.3390/cancers12082296
work_keys_str_mv AT vishnoikanchan transcriptionfactorsincancerdevelopmentandtherapy
AT viswakarmanavin transcriptionfactorsincancerdevelopmentandtherapy
AT ranaajay transcriptionfactorsincancerdevelopmentandtherapy
AT ranabasabi transcriptionfactorsincancerdevelopmentandtherapy